𝔖 Bobbio Scriptorium
✦   LIBER   ✦

National Register of Clinical Trials—A method to improve GCP compliance

✍ Scribed by Andrzej Czarnecki; Katarzyna Zalewska

Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
89 KB
Volume
7
Category
Article
ISSN
1053-8569

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized clinical trial of a psychoe
A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus
✍ Elizabeth W. Karlson; Matthew H. Liang; Holley Eaton; Jie Huang; Lisa Fitzgerald 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## Objective In a cross‐sectional study, we previously identified 2 potentially modifiable risk factors for adverse outcomes in systemic lupus erythematosus (SLE): self‐efficacy and social support. The goal of this study was to evaluate in a randomized controlled trial a theory‐based i

A randomized clinical trial of a writing
A randomized clinical trial of a writing workshop intervention to improve autobiographical memory and well-being in older adults
✍ Kate de Medeiros; Amanda Mosby; Kathryn B. Hanley; Maria Suarez Pedraza; Jason B 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 514 KB

## Abstract ## Background Despite much research on methods to improve new learning and memory in old age, there is virtually no literature on the improvement of autobiographical memory (AM). The present study assessed the effectiveness of a structured autobiographical writing workshop for improvin

The relationship of serum infliximab con
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
✍ E. William St.Clair; Carrie L. Wagner; Adedigbo A. Fasanmade; Benjamin Wang; Tho 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

## Abstract ## Objective To investigate the relationship between serum concentrations of infliximab, a monoclonal anti–tumor necrosis factor α antibody, and clinical improvement from infliximab therapy for rheumatoid arthritis (RA). ## Methods Multiple blood samples were obtained from each of 42